Forecast

There is no analyst data available for this company.

News Go to news feed

PolyPeptide: 100 CHF investment three years ago now about 79% up

If 100 CHF had been invested in PolyPeptide on 21 August 2023 (price 24.50 CHF), investors would now hold 4.082 shares worth 179.39 CHF at the closing price on 20 August 2026 (43.95 CHF), an increase of 79.39 percent. PolyPeptide’s market capitalization was most recently about 1.45 billion CHF. The calculation does not take stock splits or dividend payments into account. » More on finanzen.net
PolyPeptide confirms preliminarily reported H1 figures and raises annual forecast

PolyPeptide increased first-half 2026 revenue by nearly 42% to €236.6m and improved EBITDA to €49.1m, lifting the EBITDA margin to 20.7%. The group posted a net profit of €9.1m after a loss in the prior year; drivers were higher sales of therapies for metabolic diseases and strong utilisation of the new large-scale facility in Braine-l'Alleud. For 2026, PolyPeptide now expects revenue growth of 25–30% at constant exchange rates, an EBITDA margin in the high double-digit range, and unchanged investments of 15–20% of revenue. Separately, a takeover offer from Samsung Biologics at CHF 44.31 per share has been made; the board recommends acceptance and major shareholder Draupnir has already committed to participate. » More on finanzen.net
PolyPeptide investment five years ago would have incurred a 55.52% loss

A 100-CHF investment in PolyPeptide five years ago would have fallen to 44.48 CHF, representing a loss of 55.52%. The stock's closing price on 30 July 2026 was 43.95 CHF, and its market capitalization is around 1.45 billion CHF. The calculation does not take stock splits and dividends into account. » More on finanzen.net

Historical dividends Dividends

All dividend metrics All metrics

In 2022, POLYPEPTIDE GROUP SF -,01 has already paid 0,29€ in dividends. The last payout was in May 2022.

Financials

In the last quarter, POLYPEPTIDE GROUP SF -,01 had revenue of 236,24M€ and net profit of 9,07M€

(EUR)	Jun 2026	YoY
Revenue	+236,24M	-
Gross profit	+53,33M	-
Net profit	+9,07M	-
EBITDA	+38,76M	-

Fundamentals

Metric	Value
Market capitalization	+1,55Mld€
Number of shares	32,99M
52-week high/low	+47,00€ - +15,15€
Dividends	No
Beta	1
P/E ratio	+109,21
PEG ratio	+0,40
P/B ratio	+4,40
P/S ratio	+3,38

Company profile

Die PolyPeptide Group AG ist weltweit als Auftragsentwicklungs- und Produktionsunternehmen tätig. Sie konzentriert sich auf proprietäre und generische Peptide in GMP-Qualität, die von Pharma- und Biotech-Unternehmen in zugelassenen pharmazeutischen Produkten, Medikamenten in der klinischen Entwicklung und in generischen Produkten verwendet werden. Das Unternehmen stellt kundenspezifische Peptide in Forschungsqualität her und entwickelt Neoantigen-Peptide zur Unterstützung personalisierter Krebstherapien. Das Unternehmen ist auch an der Herstellung von Peptiden für kommerziell zugelassene Peptidtherapeutika beteiligt. Darüber hinaus stellt es peptidbasierte Generika für den Human- und Veterinärmarkt sowie kosmetische Peptide her. Darüber hinaus bietet das Unternehmen Dienstleistungen zur Unterstützung bei regulatorischen Angelegenheiten an. Das Unternehmen wurde 1952 gegründet und hat seinen Hauptsitz in Zug, Schweiz. Die PolyPeptide Group AG ist eine Tochtergesellschaft der Draupnir Holding B.V.